Sugi Holdings Co.,Ltd.
$18.990.0%YTD+16.6%1Y+16.6%
Mentions · last 7 days
0
Price updated 4m ago·X counts updated 22h ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $SGIPF, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Pharmaceuticals sits in its cycle right now — and what that implies for $SGIPF.
Medical - Pharmaceuticals
No material change from last week — Trump's executive order support and DEA rescheduling progress create a viable regulatory pathway while ATAI's pipeline advances toward multiple late-stage data..
What this means for $SGIPF
Neutral — Japanese drugstore chain operating ~1,483 retail pharmacy stores offering health products, counseling, and home healthcare services; limited read-through from medical - pharmaceuticals macro dynamics to this specific revenue mix.
Industry benchmark
5-name peer basket
+67.4%YTD
+41.7%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
17.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
8.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
4.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
0.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
10.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
31.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Jul 9, 2026$0.24$0.27-11.0%
Q1 2026Apr 9, 2026$0.33$0.30+8.5%
Q4 2025Jan 8, 2026$0.25$0.27-6.9%
Q3 2025Oct 9, 2025$0.28$0.33-15.2%
Next earningsTue, Sep 29·consensus EPS $0.31
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY27$270.4B+15773.5%30.8%4.7%$38.27—
Q4 FY26$261.0B+7.2%33.2%5.5%$51.66$0
Q3 FY26$249.5B+13.0%31.6%4.2%$39.00$0
Q2 FY26$254.4B+19.5%31.5%5.0%$41.00$0
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY27$1.07T$1.06T – $1.09T$175.47$171.21 – $183.057
FY28$1.17T$1.14T – $1.23T$194.73$190.00 – $203.137
FY29$1.24T$1.22T – $1.28T$213.58$208.39 – $222.793
FY30$1.32T$1.30T – $1.36T$244.07$238.14 – $254.604
FY31$1.41T$1.39T – $1.46T$268.40$261.88 – $279.982
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.100%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+14.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 99.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.315-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.ListedOTCListed on an over-the-counter market (PNK / OTCQB / OTCQX), not a major exchange. Lower disclosure requirements and thinner liquidity.
More in Medical - Pharmaceuticals
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $SGIPF on X in the last 7 days.